Your browser doesn't support javascript.
loading
Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.
Osterman, Mark T; Rosario, Maria; Lasch, Karen; Barocas, Morris; Wilbur, Jayson D; Dirks, Nathanael L; Gastonguay, Marc R.
Afiliação
  • Osterman MT; Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Penn Presbyterian Medical Center, Philadelphia, Pennsylvania.
  • Rosario M; Takeda Pharmaceuticals International Inc, Cambridge, Massachusetts.
  • Lasch K; Takeda Pharmaceuticals USA, Inc, Deerfield, Illinois.
  • Barocas M; Takeda Pharmaceuticals USA, Inc, Deerfield, Illinois.
  • Wilbur JD; Metrum Research Group, LLC, Tariffville, Connecticut.
  • Dirks NL; Metrum Research Group, LLC, Tariffville, Connecticut.
  • Gastonguay MR; Metrum Research Group, LLC, Tariffville, Connecticut.
Aliment Pharmacol Ther ; 49(4): 408-418, 2019 02.
Article em En | MEDLINE | ID: mdl-30663076
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Gastrointestinais / Colite Ulcerativa / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Gastrointestinais / Colite Ulcerativa / Anticorpos Monoclonais Humanizados Idioma: En Ano de publicação: 2019 Tipo de documento: Article